Search results for: 'ios security market ada'

This study explores the global immuno-oncology (I-O) markets evolution from 2020 to 2025. An extensive analysis is provided on the growth opportunities envisioned by Frost & Sullivan to help stakeholders leverage their momentum and disrupt the market by offering best-in-class solutions. The study considers oncology agents for which the immune syst...

13 May 2021  |  Global  |  Market Research

Post-COVID-19 Trends Disrupt the Global Contract Research Organization (CRO) Market

Increased Focus on Patient Centricity and Diversity in Clinical Trials Provide Growth Opportunities for CROs and Technology Vendors

Infographics

×

Frost & Sullivan presents post-COVID-19 growth opportunities and strategic imperatives in the contract research organization (CRO) market, covering the markets maturity, key participants, competitive landscape, and recent mergers and acquisitions. The study highlights key growth drivers and restraints, identifies initiatives by major global CROs, a...

24 Jul 2020  |  North America  |  Market Research

Curative Oncology and Rare Disease Therapies Transforming the Global Biologics Market, 2020–2024

Strategic Collaborations with Specialty Bio-CDMOs will Continue to Drive Growth Opportunities in Antibody-drug Conjugates and Gene Therapies

Infographics

×

Key Issues Addressed

With this research service, Frost & Sullivans Transformational Health team provides critical insights into the global biologics industry highlighting the growth opportunities, market revenue segmentation, and technology trends influencing its growth. The global biologics market covered in this study includes 4 major segments – antibody therapies, r...

21 Aug 2020  |  Global  |  Market Research

Hybridization of Clinical Trial Designs Reviving Global CRO Market Post-pandemic, 2019–2024

Patient-centric and Safety-focused Logistical Solutions will Create New Growth Opportunities

Infographics

×

In this research deliverable, Frost & Sullivan’s analyst team offers a bold perspective on the post-pandemic growth opportunities for the global CRO market. With the increased threat of COVID-19 and world-wide lockdowns in effect, the contract research organization (CROs) market is seeing interruptions in ongoing clinical trials and delays of new t...

Traditionally, CMOs have thrived by aggregating demand and delivering benefits of economies of scale. However, with the fading era of blockbuster drugs dispensed to large patient pools and shift to precision medicine, focus on niche indications, and increased R&D in biologics, pharma sponsors are increasingly turning to CMOs as strategic partners i...

19 Feb 2021  |  North America  |  Market Research

Regulatory and Infrastructure Reforms in India and China Catalyzing the Asian Specialty Generics Market

High Unmet Needs in Niche Oncology Indications will Drive Future Growth Potential

Infographics

×

Frost & Sullivans Transformational Health team provides critical insights into the Asian specialty generics market with this research service, highlighting growth opportunities, selected countries biopharmaceutical environment, and significant R&D, regulatory, and infrastructure reforms influencing its growth. The report examines similarities and c...

23 Oct 2020  |  North America  |  Market Research

Access to New Therapy Areas to Drive Major Growth in the Global Biosimilars Market, 2020–2026

Outsourced Manufacturing of the Complex Third Wave of Biosimilars to Spark New Growth Opportunities

Infographics

×

Key Issues Addressed

In this research service, the Transformational Health team at Frost & Sullivan provides critical insights into the global biosimilar industry, highlighting the key growth opportunities, market revenue forecasts, and trends that will influence the industry with the emergence of the third wave of biosimilars. The global third-wave biosimilars market ...

This study by Frost & Sullivans Healthcare and Life Sciences team provides critical insights into the US COVID-19 vaccines and therapeutics market, including developing vaccines, supply chain considerations, and requirements to manage distribution. The study also identifies actionable and profitable growth opportunities for industry participants. T...

In 2003, the first human genome sequence was produced, with a production cost between $500 million and $1 billion. However, since 2008, when next-generation sequencing (NGS) approaches entered the research setting, there has been a significant decline in sequencing costs. These approaches allow either the whole genome (via whole-genome sequencing [...